JP2021507689A - 抗体産生をモジュレートするための生体分子の細胞内送達 - Google Patents

抗体産生をモジュレートするための生体分子の細胞内送達 Download PDF

Info

Publication number
JP2021507689A
JP2021507689A JP2020530617A JP2020530617A JP2021507689A JP 2021507689 A JP2021507689 A JP 2021507689A JP 2020530617 A JP2020530617 A JP 2020530617A JP 2020530617 A JP2020530617 A JP 2020530617A JP 2021507689 A JP2021507689 A JP 2021507689A
Authority
JP
Japan
Prior art keywords
cell
cells
antibody
compound
stenosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020530617A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021507689A5 (https=
Inventor
アーモン アール． シャレイ，
アーモン アール． シャレイ，
ジョナサン ビー． ギルバート，
ジョナサン ビー． ギルバート，
Original Assignee
スクイーズ バイオテクノロジーズ カンパニー
スクイーズ バイオテクノロジーズ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スクイーズ バイオテクノロジーズ カンパニー, スクイーズ バイオテクノロジーズ カンパニー filed Critical スクイーズ バイオテクノロジーズ カンパニー
Publication of JP2021507689A publication Critical patent/JP2021507689A/ja
Publication of JP2021507689A5 publication Critical patent/JP2021507689A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2527/00—Culture process characterised by the use of mechanical forces, e.g. strain, vibration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Developmental Biology & Embryology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020530617A 2017-12-05 2018-12-04 抗体産生をモジュレートするための生体分子の細胞内送達 Pending JP2021507689A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762594981P 2017-12-05 2017-12-05
US62/594,981 2017-12-05
PCT/US2018/063931 WO2019113125A1 (en) 2017-12-05 2018-12-04 Intracellular delivery of biomolecules to modulate antibody production

Publications (2)

Publication Number Publication Date
JP2021507689A true JP2021507689A (ja) 2021-02-25
JP2021507689A5 JP2021507689A5 (https=) 2022-01-11

Family

ID=65409454

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020530617A Pending JP2021507689A (ja) 2017-12-05 2018-12-04 抗体産生をモジュレートするための生体分子の細胞内送達

Country Status (5)

Country Link
US (1) US20210317187A1 (https=)
EP (1) EP3720878A1 (https=)
JP (1) JP2021507689A (https=)
CN (1) CN111683964A (https=)
WO (1) WO2019113125A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3344575B1 (en) 2015-09-04 2020-04-15 SQZ Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
CA3023092A1 (en) 2016-05-03 2017-11-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to induce tolerance
AU2019234549B2 (en) 2018-03-12 2026-02-12 Sqz Biotechnologies Company Methods for treating HPV-associated diseases
CA3131701A1 (en) 2019-02-28 2020-09-03 Sqz Biotechnologies Company Delivery of biomolecules to pbmcs to modify an immune response
KR20210149791A (ko) 2019-04-08 2021-12-09 에스큐지 바이오테크놀로지스 컴퍼니 페이로드를 세포 내로 전달하기 위한 시스템에서 이용하기 위한 카트리지
CN115427579A (zh) * 2019-12-17 2022-12-02 阿瑞迪思医药公司 增强和加速抗体表达的方法
EP4127195A4 (en) * 2020-03-26 2024-12-11 Agency for Science, Technology and Research A method and system for introducing one or more exogenous substances into an immune cell
JP7524928B2 (ja) * 2022-07-15 2024-07-30 トヨタ自動車株式会社 電池および電池の製造方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008078673A1 (ja) * 2006-12-26 2008-07-03 Japan Science And Technology Agency Ｂ細胞におけるｃｄ２２機能を抑制することから成る免疫応答の促進方法
JP2009518033A (ja) * 2005-12-09 2009-05-07 アカデミッシュ メディッシュ セントラム ビーアイジェイ ド ユニバーシテイト バン アムステルダム 抗体産生細胞の安定性に影響を与える手段および方法
WO2017123663A1 (en) * 2016-01-12 2017-07-20 Sqz Biotechnologies Company Intracellular delivery of complexes
WO2017176806A1 (en) * 2015-04-03 2017-10-12 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b cells
WO2017192786A1 (en) * 2016-05-03 2017-11-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to induce tolerance

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9005974B2 (en) * 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
PT2768942T (pt) 2011-10-17 2020-01-21 Massachusetts Inst Technology Entrega intracelular
KR102243597B1 (ko) 2013-08-16 2021-04-26 메사추세츠 인스티튜트 오브 테크놀로지 세포로의 선택적 물질 전달
KR20170074235A (ko) * 2014-10-31 2017-06-29 메사추세츠 인스티튜트 오브 테크놀로지 면역 세포로의 생체분자의 전달

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009518033A (ja) * 2005-12-09 2009-05-07 アカデミッシュ メディッシュ セントラム ビーアイジェイ ド ユニバーシテイト バン アムステルダム 抗体産生細胞の安定性に影響を与える手段および方法
WO2008078673A1 (ja) * 2006-12-26 2008-07-03 Japan Science And Technology Agency Ｂ細胞におけるｃｄ２２機能を抑制することから成る免疫応答の促進方法
WO2017176806A1 (en) * 2015-04-03 2017-10-12 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b cells
WO2017123663A1 (en) * 2016-01-12 2017-07-20 Sqz Biotechnologies Company Intracellular delivery of complexes
WO2017192786A1 (en) * 2016-05-03 2017-11-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to induce tolerance

Also Published As

Publication number Publication date
WO2019113125A1 (en) 2019-06-13
CN111683964A (zh) 2020-09-18
EP3720878A1 (en) 2020-10-14
US20210317187A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
JP2021507689A (ja) 抗体産生をモジュレートするための生体分子の細胞内送達
JP7046795B2 (ja) 細孔を有する表面によって媒介される生体分子の細胞内送達
RU2747878C2 (ru) Внутриклеточная доставка биомолекул для индукции толерантности
JP2021176904A (ja) 寛容性を誘導するための生体分子の細胞内送達
JP7053601B2 (ja) Ｂ細胞リンパ球をスクリーニングする方法
EP3402890B1 (en) Intracellular delivery of complexes
US20210388390A1 (en) Intracellular delivery of biomolecules to enhance antigen presenting cell function
US12060570B2 (en) Vector-free intracellular delivery by reversible permeabilisation
US20250257322A1 (en) Modified hematopoietic stem cells and uses thereof
US20250270592A1 (en) Reprogramming of cells with self-amplifying rna

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211206

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230804